Drug Research
BI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac Meets Primary and Secondary Endpoints
VBI Vaccines Inc. (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported top-line data from CONSTANT, the second pivotal Phase 3 study, assessing lot-to-lot manufacturing consistency of Sci-B-Vac®, the company’s trivalent hepatitis B (HBV) vaccine,...
Drug Research
Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
Generation Bio, a company leading a new generation of gene therapy, announced the closing of a $110 million Series C financing. Proceeds will be used to advance the company’s two lead liver-targeted programs for hemophilia A and phenylketonuria (PKU)...
Drug Research
Bayer and Exscientia collaborate to leverage the potential of AI in cardiovascular and oncology drug discovery
Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia’s proprietary AI drug discovery platform and drug design know-how with...
Drug Research
Development of First-In-Class Antibody Therapeutics and New Acquisition Brings Hope to Patients with Fibrotic and Inflammatory Diseases
The breakthrough discovery of investigational therapies for multiple human diseases by a team of Singapore clinicians, clinician scientists and scientists from National Heart Centre Singapore (NHCS), SingHealth Duke-NUS AMC and the Singapore based biotech company Enleofen Bio, along with...
Drug Research
Velabs Therapeutics Receives Exclusive Licence from Alytas Therapeutics for the Development of Therapeutic Antibodies as Senolytics
Velabs Therapeutics GmbH, a biotech company focused on the rapid screening of functional therapeutic antibodies announced that it has entered into an exclusive licence agreement with alytas therapeutics GmbH , for the development and commercialization of alytas’ antibodies in...
Drug Research
BeiGene obtains certain rights for Leap Therapeutics cancer drug
Chinese biopharmaceutical firm BeiGene has agreed to exclusive rights to develop and commercialise Leap Therapeutics’ cancer drug DKN-01 in the Asia Pacific region, excluding Japan.
Under the agreement, Leap will continue to have sole rights to develop, manufacture and commercialise...
Drug Research
Arena Pharmaceuticals and Beacon Discovery Expand Strategic Relationship Focusing on Multiple Immune and Inflammatory Targets
Arena Pharmaceuticals, Inc. and Beacon Discovery announced that they entered into a strategic multi-year partnership (Project Cabrillo) aimed at building novel medicines across a range of G protein-coupled receptor (GPCR) targets.
Under the terms of the deal, Beacon will be...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
